Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tumor heterogeneity is well documented for many characters, including the production of growth factors, which improve tumor proliferation and promote resistance against apoptosis and against immune reaction. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment. While it has been suggested that therapies targeting growth factors are robust against evolved resistance, current therapies against growth factors, like antiangiogenic drugs, are not effective in the long term, as resistant mutants can evolve and lead to relapse. We use evolutionary game theory to study the dynamics of the production of growth factors by monolayers of cancer cells and to understand the effect of therapies that target growth factors. The dynamics depend on the production cost of the growth factor, on its diffusion range and on the type of benefit it confers to the cells. Stable heterogeneity is a typical outcome of the dynamics, while a pure equilibrium of nonproducer cells is possible under certain conditions. Such pure equilibrium can be the goal of new anticancer therapies. We show that current therapies, instead, can be effective only if growth factors are almost completely eliminated and if the reduction is almost immediate.

Original languageEnglish (US)
Pages (from-to)1146-1159
Number of pages14
JournalEvolutionary Applications
Volume6
Issue number8
DOIs
StatePublished - Dec 1 2013

Fingerprint

production economics
growth factors
cancer
Intercellular Signaling Peptides and Proteins
therapeutics
Neoplasms
tumor
Therapeutics
Game Theory
game theory
evolutionary theory
neoplasms
apoptosis
relapse
production cost
neoplasm cells
therapy
production costs
targeting
drug

All Science Journal Classification (ASJC) codes

  • Ecology, Evolution, Behavior and Systematics
  • Genetics
  • Agricultural and Biological Sciences(all)

Cite this

@article{9b5ab3af838c4a869bc5262f3810ae99,
title = "Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies",
abstract = "Tumor heterogeneity is well documented for many characters, including the production of growth factors, which improve tumor proliferation and promote resistance against apoptosis and against immune reaction. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment. While it has been suggested that therapies targeting growth factors are robust against evolved resistance, current therapies against growth factors, like antiangiogenic drugs, are not effective in the long term, as resistant mutants can evolve and lead to relapse. We use evolutionary game theory to study the dynamics of the production of growth factors by monolayers of cancer cells and to understand the effect of therapies that target growth factors. The dynamics depend on the production cost of the growth factor, on its diffusion range and on the type of benefit it confers to the cells. Stable heterogeneity is a typical outcome of the dynamics, while a pure equilibrium of nonproducer cells is possible under certain conditions. Such pure equilibrium can be the goal of new anticancer therapies. We show that current therapies, instead, can be effective only if growth factors are almost completely eliminated and if the reduction is almost immediate.",
author = "Marco Archetti",
year = "2013",
month = "12",
day = "1",
doi = "10.1111/eva.12092",
language = "English (US)",
volume = "6",
pages = "1146--1159",
journal = "Evolutionary Applications",
issn = "1752-4563",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies

AU - Archetti, Marco

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Tumor heterogeneity is well documented for many characters, including the production of growth factors, which improve tumor proliferation and promote resistance against apoptosis and against immune reaction. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment. While it has been suggested that therapies targeting growth factors are robust against evolved resistance, current therapies against growth factors, like antiangiogenic drugs, are not effective in the long term, as resistant mutants can evolve and lead to relapse. We use evolutionary game theory to study the dynamics of the production of growth factors by monolayers of cancer cells and to understand the effect of therapies that target growth factors. The dynamics depend on the production cost of the growth factor, on its diffusion range and on the type of benefit it confers to the cells. Stable heterogeneity is a typical outcome of the dynamics, while a pure equilibrium of nonproducer cells is possible under certain conditions. Such pure equilibrium can be the goal of new anticancer therapies. We show that current therapies, instead, can be effective only if growth factors are almost completely eliminated and if the reduction is almost immediate.

AB - Tumor heterogeneity is well documented for many characters, including the production of growth factors, which improve tumor proliferation and promote resistance against apoptosis and against immune reaction. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment. While it has been suggested that therapies targeting growth factors are robust against evolved resistance, current therapies against growth factors, like antiangiogenic drugs, are not effective in the long term, as resistant mutants can evolve and lead to relapse. We use evolutionary game theory to study the dynamics of the production of growth factors by monolayers of cancer cells and to understand the effect of therapies that target growth factors. The dynamics depend on the production cost of the growth factor, on its diffusion range and on the type of benefit it confers to the cells. Stable heterogeneity is a typical outcome of the dynamics, while a pure equilibrium of nonproducer cells is possible under certain conditions. Such pure equilibrium can be the goal of new anticancer therapies. We show that current therapies, instead, can be effective only if growth factors are almost completely eliminated and if the reduction is almost immediate.

UR - http://www.scopus.com/inward/record.url?scp=84889666334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889666334&partnerID=8YFLogxK

U2 - 10.1111/eva.12092

DO - 10.1111/eva.12092

M3 - Article

AN - SCOPUS:84889666334

VL - 6

SP - 1146

EP - 1159

JO - Evolutionary Applications

JF - Evolutionary Applications

SN - 1752-4563

IS - 8

ER -